Get the Stockscreener App
0.3789
3.05%
0.0112
Pre-market:
.37
-0.0089
-2.35%
Plus Therapeutics Inc stock is traded at $0.3789, with a volume of 11.73M.
It is up +3.05% in the last 24 hours and down -41.52% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.3677
Open:
$0.346
24h Volume:
11.73M
Relative Volume:
0.61
Market Cap:
$6.44M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.1498
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+30.16%
1M Performance:
-41.52%
6M Performance:
-71.72%
1Y Performance:
-83.16%
1-Day Range:
$0.346
$0.45
1-Week Range:
$0.268
$0.661
52-Week Range:
$0.26
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.3789 | 4.95M | 0 | -12.89M | -11.95M | -2.53 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com
Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times
PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister
DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail
3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail
Plus Therapeutics recives Nasdaq delinquency notice - MSN
Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus
Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus
Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus
Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire
Plus Therapeutics Receives Nasdaq Warning: Company Has 60 Days to Submit Compliance Plan - Stock Titan
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks
Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail
Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail
Plus Therapeutics Delays Quarterly Report Filing - TipRanks
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN
Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Con - GuruFocus
Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in - GuruFocus
Plus Therapeutics Presents Promising ReSPECT Trial Data on REYOBIQ for Leptomeningeal Metastases at 2025 Nuclear Medicine and Neurooncology Conference - Nasdaq
Plus Therapeutics reports progress in CNS cancer therapy - Investing.com
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and - GlobeNewswire
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - TradingView
Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Conference | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Expected to Announce Earnings on Wednesday - Defense World
Leptomeningeal Metastases Pipeline 2025: Key Companies, MOA, - openPR.com
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World
Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World
Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus
Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Plus Therapeutics (PSTV) Receives Downgrade to Hold by D. Boral Capital | PSTV Stock News - GuruFocus
PSTV Stock Sees Decline of Approximately -22.86% in Last Five Days - knoxdaily.com
Form 8-KCurrent report - ADVFN
Plus Therapeutics Inc (PSTV) can make a big difference with a little luck - Sete News
Investing in Plus Therapeutics Inc (PSTV): What You Must Know - knoxdaily.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):